Médecine

Paramédical

Autres domaines


S'abonner

Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali - 13/07/19

Doi : 10.1016/j.arcped.2019.06.002 
M. Sylla a, b, , O. Dolo b, A.I. Maiga b, c, F.T. Traore b, Y.A. Coulibaly a, J. Togo b, D.B. Fofana d, F. Dicko-Traore a, S. Doumbia e, S. Orsega h, S. Diallo e, R.L. Murphy f, V. Calvez g, A.G. Marcelin g
a Department of Pediatrics, University Hospital Gabriel Toure, Bamako, Mali 
b Unit for Epidemiology and Molecular of HIV Drug Resistance, SEREFO/UCRC, FMOS, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali 
c Department of Medical Biology, University Hospital Gabriel Toure, Bamako, Mali 
d FMOS, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali 
e University Clinical Research Center, UCRC, Bamako, Mali 
f Northwestern University, Chicago, IL, USA 
g Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, France 
h National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA 

Corresponding author. Department of Pediatrics, Gabriel Toure Hospital, University of Sciences, Techniques and Technologies of Bamako (USTTB), BP 267, Bamako, Mali.Department of Pediatrics, Gabriel Toure Hospital, University of Sciences, Techniques and Technologies of Bamako (USTTB)BP 267BamakoMali
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 13 juillet 2019
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Introduction

In recent years, children born to HIV-infected mothers have been receiving antiretroviral treatment (ART) with limited or no virologic monitoring, which increases the likelihood of development and accumulation of drug resistance mutations, which itself may limit the effectiveness of future ART. The objective of this study was to evaluate the prevalence of resistance mutations in children infected with HIV-1 experiencing virological failure to second-line ART in the Pediatric Department of Gabriel Touré Hospital in Mali.

Methods

Children aged from 5 to 18 infected with HIV-1 on second-line antiretroviral therapy and whose viral load was greater than 1000 copies/mL after observance reinforcement were enrolled. The protease and reverse transcriptase genes were sequenced with ViroSeq®. The results were interpreted according to the last version of the Stanford algorithm in 2018. The study was approved by the Ethics Committee of the Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies of Bamako (Mali).

Results

Of 216 children, 33 (15.3%) who had a viral load (VL)>1000 copies/mL in second line were recruited and included in the study. The median plasma viral load was 77,000 copies/mL [IQR (28,000–290,000)] and the median CD4 cell count was 310 cells/mm3 [IQR (152–412)]. The median age was 12 years; 48.5% of patients were treated with a combination of stavudine/lamivudine/nevirapine (Triomune®) for first-line treatment and 60.6% with abacavir/lamivudine/lopinavir/ritonavir for the second-line ART. The median treatment duration was 8.5 years [range, 3–13]. Of the 33 children whose treatment failed, the predominant HIV-1 subtype was CRF02_AG (66.7%). The prevalence of resistance to ART classes was 60.61% (20/33) to nucleoside reverse transcriptase inhibitors (NRTIs), 54.51% (18/33) to nonnucleoside reverse transcriptase inhibitors (NNRTIs), and 51.52% (17/33) to protease inhibitors (PIs). Of the patients studied, 90.9% were exposed to lopinavir/ritonavir (LPV/r) but only 15.2% (5/33) developed resistance to LPV/r.

Conclusions

This study demonstrated that LPV/r remains active in most patients after second-line ART failure. In children whose second-line ART fails, particular attention should be paid to their ART and adherence history when considering the next treatment option.

Le texte complet de cet article est disponible en PDF.

Keywords : HIV-1, Children, Second-line ART, Drug resistance


Plan


© 2019  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.